Biomaxima SA

As of March 31, 2026, Biomaxima SA carries a market capitalization of 47.17M, placing it among publicly traded companies globally. Its enterprise value stands at 62.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biomaxima SA's next confirmed earnings release is scheduled for December 2, 2026.

As of March 31, 2026, Biomaxima SA has 4.19M shares outstanding.

As of March 31, 2026, Biomaxima SA trades at a trailing price-to-earnings ratio of 45.94. The price-to-sales ratio is 0.77, and the price-to-book ratio stands at 0.98.

As of March 31, 2026, Biomaxima SA trades at an EV/EBITDA multiple of 10.55 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 28.18 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Biomaxima SA trades at an EV/FCF ratio of 39.40, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 62.87M versus a market cap of 47.17M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Biomaxima SA maintains a current ratio of 1.39, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.62, indicating elevated leverage, while an interest coverage ratio of 5.71 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Biomaxima SA posted a return on equity (ROE) of 2.17, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.90 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.33, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.00, useful for judging operating efficiency across full business cycles. The company generates approximately 461,836.43 in revenue per employee across its workforce of 134.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.31 indicates how many times Biomaxima SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Biomaxima SA recorded 229,000.00 in income tax expense. That works out to an effective tax rate of 18.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.27M, leaving 1.04M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Biomaxima SA's stock has declined approximately 25.38% over the past 52 weeks. The 50-day moving average sits at 10.07, while the 200-day moving average is 10.90.

Over the twelve months ended March 31, 2026, Biomaxima SA generated 62.12M in revenue and converted that into 1.04M in net income, yielding earnings per share of 0.24. EBITDA reached 5.96M, while operating income came in at 815,000.00.

As of March 31, 2026, Biomaxima SA holds 423,000.00 in cash and equivalents against 16.12M in total debt, resulting in a net debt position of 13.22M. Total book value stands at 47.96M, with working capital of 7.96M providing operational flexibility.

Biomaxima SA produced 1.05M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -308,000.00 in capital expenditures, free cash flow totaled 740,000.00 - equivalent to 0.17 per share.

Over the twelve months ended March 31, 2026, Biomaxima SA posted a gross margin of 47.37, reflecting its pricing power and cost economics. The operating margin of 1.31 and net profit margin of 1.67 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 1.55, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.45, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Biomaxima SA shareholders.

As of March 31, 2026, Biomaxima SA has an Altman Z-Score of 2.42, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.